USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
05 Jan 2022 | 03:45 PM GMT

Companion DTx: Clinical and economic evidence

Anchored by:

Alexander Klein
Founder & CEO
NEDICARE
Matt Norton
VP of Marketing & Commercial Development
S3 CONNECTED HEALTH

Participants:

Alexander Klein Founder & CEONedicare
Alexander Klein
Founder & CEONedicare
Matt Norton VP of Marketing & Commercial DevelopmentS3 Connected Health
Matt Norton
VP of Marketing & Commercial DevelopmentS3 Connected Health
Chandana Fitzgerald President, CommunityHLTH
Chandana Fitzgerald
President, CommunityHLTH
Abhishek Shah Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Abhishek Shah
Co-Founder & CEOWellthy Therapeutics Pvt. Ltd.
Adam Abrahami Senior ConsultantMaya Health
Adam Abrahami
Senior ConsultantMaya Health
Chris Wasden Chief Strategy OfficerTwill
Chris Wasden
Chief Strategy OfficerTwill
Christopher Hall Commercial Director, APACMarula Health
Christopher Hall
Commercial Director, APACMarula Health
Dr. Nick (Nemanja) Kovacev Head of Healthcare and Life Sciences PracticeHTEC Group
Dr. Nick (Nemanja) Kovacev
Head of Healthcare and Life Sciences PracticeHTEC Group
Jin Lee Director of Digital HealthAstellas Pharma, Inc
Jin Lee
Director of Digital HealthAstellas Pharma, Inc
Klaus Suwelack NBD & Innovation ManagmentJanssen
Klaus Suwelack
NBD & Innovation ManagmentJanssen
Mark Grossman VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Mark Grossman
VP of Growth Initiatives & Market PartnersGoMo Health - Engagement that Works
Richie Bavasso PresidentPneumoWave
Richie Bavasso
PresidentPneumoWave

About this Meeting

Commercialization of DTx solutions as digital drug companions seems to be a valuable route to market for DTx companies and a good option for pharma companies, which are still wary of incorporating standalone DTx in their portfolios. However, there are still a lot of questions around the evidence generation for companion DTx. Join us in this informal conversation where we will talk about:   

  •  Level of clinical and economic evidence required - how does this change depending on the stakeholder, mode of action, risk of the product, etc?
  •  Companion DTx and drugs are currently regulated separately; but when it comes to clinical evidence, should DTx - drug be validated together? What are the barriers and challenges to do this?  
  •  Particularities of the study design for companion DTx.  
  •  Role of the DTx company vs. role of pharma in evidence generation  
  •  What is the most efficient way to generate economic evidence?